Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.75 |
| ▸ | GRM5 | P41594 | 7/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 5/20 | 0.62 |
| ▸ | GBA1 | P04062 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29704545 | 1.00 | RAB9A (0.75) | RAB9AGRM5MEN1KMT2AKDM4E | |
| Acetic Acid SCHEMBL4119499 | 0.96 | RAB9A (0.70) | RAB9AGRM5MEN1KMT2AKDM4E | |
| SCHEMBL821844 | 0.87 | KDM4E (0.71) | RAB9AGRM5MEN1KMT2AKDM4E | |
| SCHEMBL31725239 | 0.86 | RAB9A (0.78) | RAB9AGRM5MEN1KMT2ANPC1 | |
| SCHEMBL3119185 | 0.86 | RAB9A (0.78) | RAB9AGRM5MEN1KMT2ANPC1 | |
| SCHEMBL14353530 | 0.86 | RAB9A (1.00) | RAB9AGRM5MEN1KMT2ALMNA | |
| SCHEMBL5631286 | 0.82 | RAB9A (0.72) | RAB9AGRM5MEN1KMT2ANPC1 | |
| SCHEMBL5034141 | 0.82 | RAB9A (0.72) | RAB9AGRM5MEN1KMT2ANPC1 | |
| SCHEMBL30509648 | 0.82 | RAB9A (0.72) | RAB9AGRM5MEN1KMT2ANPC1 | |
| SCHEMBL6663529 | 0.82 | RAB9A (0.66) | RAB9AGRM5MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730141-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | Pfizer Limited (GB) | 2006-12-13 | — | — | EP | claimed |
| WO-2005092887-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | claimed |
| EP-0500616-B1 | OLIGOMERIC TO POLYMERIC CHARACTER COMPLEXES | ATOTECH DEUTSCHLAND GMBH (DE) | 1998-01-07 | — | — | EP | claimed |
| US-5503877-A | ORGANONITROGEN, ORGANOMETALLIC POLYMERS OR OLIGOMERS;REDUCTION | ATOTECH DEUTSCHALND GMBH (DE) | 1996-04-02 | — | — | US | claimed |
| US-4021437-A | 6-Ethylamino-2-picoline from 6-acetamido-2-picoline | STERLING DRUG INC. (US) | 1977-05-03 | — | — | US | claimed |
| EP-3728368-B1 | METHOD FOR REDUCTION OF ALDEHYDE EMISSION IN POLYURETHANE COMPRISING MATERIALS | HUNTSMAN INT LLC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-12129330-B2 | Method for reduction of aldehyde emission in polyurethane comprising materials | HUNTSMAN INTERNATIONAL LLC | 2024-10-29 | — | — | US | disclosed |
| US-20240166793-A1 | METHOD FOR REDUCTION OF ALDEHYDE EMISSION IN POLYURETHANE COMPRISING MATERIALS | HUNTSMAN INTERNATIONAL LLC | 2024-05-23 | — | — | US | disclosed |
| EP-3356345-B1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-08 | — | — | EP | disclosed |
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
| US-20230174540-A1 | 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| WO-2023081854-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2023-05-11 | — | — | WO | disclosed |
| US-4689342-A | MITICIDES, NEMATOCIDES | ROUSSEL UCLAF (FR) | 1987-08-25 | — | — | US | disclosed |
| EP-0110769-B1 | ESTERS DERIVED FROM 2,2-DIMETHYLCYCLOPROPANE-CARBOXYLIC ACIDS AND BIARYL ALCOHOLS, PROCESS FOR THEIR PREPARATION, THEIR USE AS PARASITICIDES AND COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1986-03-05 | — | — | EP | disclosed |
| EP-0110769-A1 | Esters derived from 2,2-dimethylcyclopropane-carboxylic acids and biaryl alcohols, process for their preparation, their use as parasiticides and compositions containing them | ROUSSEL-UCLAF (FR) | 1984-06-13 | — | — | EP | disclosed |
| US-4203988-A | ANTISECRETORY AGENTS | MERCK & CO., INC. (US) | 1980-05-20 | — | — | US | disclosed |
| US-4118557-A | Cyclic alkylidenyl N-(lower-alkyl)-3-(pyridinyl)anilinomethylenemalonates | STERLING DRUG INC. (US) | 1978-10-03 | — | — | US | disclosed |
| US-4021437-A | 6-Ethylamino-2-picoline from 6-acetamido-2-picoline | STERLING DRUG INC. (US) | 1977-05-03 | — | — | US | disclosed |
| US-4021437-A | 6-Ethylamino-2-picoline from 6-acetamido-2-picoline | STERLING DRUG INC. (US) | 1977-05-03 | — | — | US | disclosed |
| US-4021437-A | 6-Ethylamino-2-picoline from 6-acetamido-2-picoline | STERLING DRUG INC. (US) | 1977-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | RAB9A 1430/4885GRM5 3312/4885MEN1 1926/4885 |
| US-20230174540-A1 | 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, PKD2 | RAB9A 3922/4885GRM5 154/4885MEN1 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.